CAMBRIDGE, MASSACHUSETTS and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct 26, 2015) - VBI Vaccines Inc. (VBIV) ("VBI") and SciVac Therapeutics Inc. (VAC.TO)(SVACF) ("SciVac") announced today that ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today ...
Sanofi Pasteur has chosen VBI's LPV™ technology to develop a more stable formulation of a key Sanofi Pasteur vaccine candidate. The collaboration will leverage VBI's LPV™ technology, which allows for ...
- New preclinical data demonstrate VBI-2905 induced robust neutralizing and antibody binding activity, as a 2-dose course and as a single booster dose, against COVID-19 and variants of concern ...
CAMBRIDGE, Mass., Sept. 14, 2015 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") is pleased to announce the promotion of Dr. David E. Anderson, Ph.D., to Chief Scientific Officer. Dr.
VBI’s manufacturing capabilities and certain related assets at Rehovot manufacturing facility Intellectual property for VBI-2601, VBI’s hepatitis B immunotherapeutic candidate Exclusive Asia Pacific ...
- VBI-2901 and VBI-2902 selected as trivalent and monovalent coronavirus vaccine candidates, respectively, for an adaptive Phase 1/2 clinical study expected to begin around year-end 2020, subject to ...
CAMBRIDGE, Mass., Feb. 09, 2016 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI") has entered into a research collaboration with GlaxoSmithKline Biologicals SA ("GSK") to evaluate VBI's LPV™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results